New hope for deadly lung cancer? trial tests promising drug combo
NCT ID NCT07200947
Summary
This study is testing a new combination treatment for people with an aggressive, hard-to-treat type of advanced lung cancer. It combines a new two-in-one immunotherapy drug (which targets two different immune system pathways) with standard chemotherapy. The goal is to see if this combination can better control the cancer and is safe for patients who have not had any prior treatment for their advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital
Beijing, Beijing Municipality, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.